NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
August 10, 2004 • Volume 1 / Number 32 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Novel Chemotherapy Agent for Solid Tumors and Lymphomas

Name of the Trial
Phase I Study of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) with Evaluation of HSP-90 Client Proteins in Patients with Solid Tumors and Lymphomas (NCI-04-C-0218). See the protocol summary at

Dr. Barbara Conley Principal Investigators
Dr. Barbara Conley and Dr. Patricia Steeg, NCI's Center for Cancer Research

Why Is This Trial Important?
Heat shock proteins (HSPs) are found in every cell of the body. HSPs help cells survive stressful conditions (including heat, cold, nutrient starvation, and oxygen deprivation) by protecting other proteins. Under nonstressful conditions, HSPs help proteins achieve and maintain their proper shape. Furthermore, HSPs help regulate the activity of proteins involved in important cellular processes, such as cell division and signal transduction (i.e., the process by which cells receive and act on external signals, including hormones and growth factors). Researchers at NCI are investigating a particular HSP, called HSP-90, as a target for cancer therapy. HSP-90 is found in greater amounts in cancer cells than in normal cells.

In this trial, researchers are trying to determine whether 17-DMAG, an HSP-90 inhibitor developed by NCI, will help prevent cancer cells from growing in patients with solid tumors or lymphomas. Solid tumors include cancers of body tissues other than the blood, bone marrow, or lymphatic system.

"HSP-90's importance in the growth and survival of cancer cells was discovered in the lab of Dr. Len Neckers at NCI," said Dr. Conley. "That research, along with the work of other NCI and extramural investigators, potentially offers a new therapeutic target that is expressed in a wide range of cancer types."

Who Can Join This Trial?
Researchers seek to enroll 40 patients aged 18 or over with either solid tumor malignancy or lymphoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are associated with minimal survival benefit. See the full list of eligibility criteria for this study at

Where Is This Trial Taking Place?
The study will be done at the NIH Clinical Center in Bethesda, Md.

Who to Contact
Contact the NCI Clinical Studies Support Center (CSSC) at 1-888-NCI-1937. The call is toll free and confidential.

An archive of "Featured Clinical Trial" columns is available at